NCT01867879View on ClinicalTrials.gov

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

April 30, 2015

Conditions
Advanced Solid Tumors (Excluding Breast Cancer)
Interventions
DRUG

TAS-102

35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.

DRUG

Placebo

Placebo tablets, orally, single dose.

Trial Locations (1)

37203

Sarah Cannon Research Institute, Nashville

All Listed Sponsors
lead

Taiho Oncology, Inc.

INDUSTRY

NCT01867879 - Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter